The study of psilocybin-assisted psychotherapy in adults with Alcohol Use Disorder

illustrative image

The company Clairvoyant Therapeutics is enrolling patients into the clinical trial investigating Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD).

The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question[s] it aims to answer are: - Does treatment with psilocybin and therapy help reduce alcohol consumption more than placebo and therapy? - Is treatment with psilocybin and therapy safe for participants? Participants will - Attend 13 study visits - Take part in therapy sessions including 2 treatment sessions with either psilocybin or placebo - Record their daily alcohol consumption on study specific device Researchers will compare psilocybin and placebo groups to see if alcohol consumption is decreased.

The trial is designed to enroll male and female 18 Years to 70 Years and is being conducted in the Sabi Mind, Calgary, Alberta, Canada; Okanagan Clinical Trials, Kelowna, British Columbia, Canada.

The study start date is November 2, 2022.

The patients that can be enrolled into this study include:

  • Moderate to severe diagnosis of AUD as measured by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria using Structured Clinical Interview for DSM-5 by the investigator.
  • Expressed a wish to reduce or stop alcohol consumption. 
  • Generally healthy with no unstable medical conditions, as determined by medical history, physical examination, routine blood labs, electrocardiogram, urine analysis, and urine toxicology.

    Exclusion Criteria
  • Diagnosed with or having a family history of any of the following concomitant psychiatric disorders: schizophrenia or prodromal symptoms, any bipolar disorder, obsessive compulsive disorder, or other psychotic episode.
  • Recent (within last 12 months) diagnosis of a major depressive disorder (MDD) (HAM-D score >19), treatment resistant depression (TRD), post-traumatic stress disorder (PTSD), panic disorder, or eating disorders.
  • Subjects deemed unfit for psilocybin-assisted therapy based on the assessments made during psychotherapy sessions prior to the first psilocybin-assisted psychotherapy session.
  • History of hallucinogen use disorder, or any use in the past 1 year, or >25 lifetime uses.

This page provides a more detailed overview of this clinical trial:

Upcoming Clinical Trials